Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.80
PTX's Cash to Debt is ranked higher than
58% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. PTX: 0.80 )
PTX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.8

Equity to Asset 0.40
PTX's Equity to Asset is ranked higher than
51% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. PTX: 0.40 )
PTX' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.99
Current: 0.4

0.06
0.99
F-Score: 3
Z-Score: 1.07
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -64.40
PTX's Operating margin (%) is ranked lower than
51% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. PTX: -64.40 )
PTX' s 10-Year Operating margin (%) Range
Min: -64.4   Max: 38.22
Current: -64.4

-64.4
38.22
Net-margin (%) -30.20
PTX's Net-margin (%) is ranked higher than
50% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. PTX: -30.20 )
PTX' s 10-Year Net-margin (%) Range
Min: -91.07   Max: 33.08
Current: -30.2

-91.07
33.08
ROE (%) -23.15
PTX's ROE (%) is ranked higher than
50% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. PTX: -23.15 )
PTX' s 10-Year ROE (%) Range
Min: -42.57   Max: 174.14
Current: -23.15

-42.57
174.14
ROA (%) -12.13
PTX's ROA (%) is ranked higher than
52% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. PTX: -12.13 )
PTX' s 10-Year ROA (%) Range
Min: -17.39   Max: 68.89
Current: -12.13

-17.39
68.89
ROC (Joel Greenblatt) (%) -360.99
PTX's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. PTX: -360.99 )
PTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -360.99   Max: 6630.22
Current: -360.99

-360.99
6630.22
Revenue Growth (%) 17.90
PTX's Revenue Growth (%) is ranked higher than
83% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. PTX: 17.90 )
PTX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 107
Current: 17.9

0
107
» PTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

PTX Guru Trades in

Q4 2012

PTX Guru Trades in Q4 2012

Jim Simons 78,000 sh (-11.86%)
» More
Q1 2013

PTX Guru Trades in Q1 2013

Jim Simons 48,953 sh (-37.24%)
» More
Q2 2013

PTX Guru Trades in Q2 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PTX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.90
PTX's P/B is ranked higher than
71% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. PTX: 2.90 )
PTX' s 10-Year P/B Range
Min: 0.26   Max: 14.61
Current: 2.9

0.26
14.61
P/S 3.60
PTX's P/S is ranked higher than
68% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. PTX: 3.60 )
PTX' s 10-Year P/S Range
Min: 0.07   Max: 8.78
Current: 3.6

0.07
8.78
EV-to-EBIT -5.40
PTX's EV-to-EBIT is ranked lower than
59% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. PTX: -5.40 )
PTX' s 10-Year EV-to-EBIT Range
Min: 6   Max: 280.5
Current: -5.4

6
280.5
Current Ratio 1.87
PTX's Current Ratio is ranked higher than
64% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. PTX: 1.87 )
PTX' s 10-Year Current Ratio Range
Min: 0.84   Max: 64.5
Current: 1.87

0.84
64.5
Quick Ratio 1.70
PTX's Quick Ratio is ranked higher than
70% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. PTX: 1.70 )
PTX' s 10-Year Quick Ratio Range
Min: 0.62   Max: 64.5
Current: 1.7

0.62
64.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 3.90
PTX's Price/DCF (Projected) is ranked higher than
81% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PTX: 3.90 )
PTX' s 10-Year Price/DCF (Projected) Range
Min: 0.2   Max: 18
Current: 3.9

0.2
18
Price/Median PS Value 2.10
PTX's Price/Median PS Value is ranked higher than
55% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. PTX: 2.10 )
PTX' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 5
Current: 2.1

0.06
5
Earnings Yield (Greenblatt) 7.30
PTX's Earnings Yield (Greenblatt) is ranked higher than
82% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. PTX: 7.30 )
PTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 16.7
Current: 7.3

0.4
16.7
Forward Rate of Return (Yacktman) 33.43
PTX's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. PTX: 33.43 )
PTX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -222.4   Max: 31.6
Current: 33.43

-222.4
31.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:GTAP.Germany
Pernix Therapeutics Holdings, Inc. was incorporated in November 1996. The Company is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a variety of therapeutic areas. The Company manages a portfolio of branded and generic products and theobromine, a non-codeine, cough suppressant product candidate in development. Its branded products for the pediatrics market include CEDAX, an antibiotic for middle ear infections, NATROBA, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC and a family of prescription treatments for cough and cold (BROVEX, ALDEX and PEDIATEX). The Company also markets REZYST IM, a proprietary probiotic blend to promote dietary management. The Company promotes its branded products through an established U.S. sales force. The Company also markets generic products through its wholly-owned subsidiary, Macoven Pharmaceuticals. Its sales force, which consists of approximately 55 full-time sales representatives as of December 31, 2011, promotes its ALDEX, BROVEX, CEDAX, PEDIATEX, REZYST and NATROBA families of branded products primarily in highly populated states, targeting pediatric and high-prescribing physicians that are in the top decile of physicians that prescribe its products. The products of the Company face competition from a variety of similar therapeutic branded and generic products. The Company's product candidates and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the DEA and other regulatory agencies in the United States and by comparable European authorities.
» More Articles for PTX

Headlines

Articles On GuruFocus.com
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Nov 12 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Aug 16 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Gyrotron Technology Inc. Elects Jan H. Loeb to Its Board of Directors Jul 22 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 25 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 19 2014
Follow-up: Pernix Therapeutics upgraded at Aegis May 27 2014
Pernix Therapeutics upgraded to Buy from Hold at Aegis May 27 2014
Pernix Therapeutics upgraded by Aegis Capital May 27 2014
Pernix Therapeutics management to meet with Needham May 21 2014
Nasdaq stocks posting largest percentage increases May 20 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Financials May 20 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 16 2014
Why Pernix Therapeutics (PTX) Is Higher This Morning May 15 2014
Pernix Therapeutics upgraded to Strong Buy from Buy at Needham May 15 2014
Pernix Therapeutics upgraded at Needham May 15 2014
Aura Of Light Shines On Pernix Shares Following Treximet Acquisition May 14 2014
Midday movers: Kate Spade, Macy's, Zulily & More May 14 2014
Why Pernix Therapeutics (PTX) Soared to a One-Year High Today May 14 2014
Pernix says Treximet has four Orange Book patents May 14 2014
Pernix sees Treximet acquisition closing no later than August 1 May 14 2014
Pernix to buy U.S. marketing rights to GSK, Pozen migraine drug May 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide